IRLAB is focused on PD and other central nervous system (CNS) disorders. Its ISP discovery platform has been validated by the progress of lead assets mesdopetam and pirepemat. Mesdopetam did not reach statistical significance on the primary endpoint (good ON-time) in a Phase IIb trial for levodopa-induced dyskinesias, but demonstrated significant ON-phase anti-dyskinetic efficacy, measured by UDysRS. IRLAB’s end-of-Phase II meeting with the FDA concluded with an endorsement for management’s plans for a Phase III programme; partnering talks are currently a top strategic priority. Pirepemat is in a Phase IIb trial for impaired balance and falls in PD; patient enrolment was completed in September with results expected at end-Q125. Phase I studies for IRL757 (for apathy in neurological conditions) are ongoing with updates expected in Q125; the programme is financially supported by the MJFF and MSRD through proof-of-concept. IRLAB is also developing two preclinical assets, IRL942 and IRL1117, for various CNS indications.